FR22C1027I1 - Formulations stabilizing and inhibiting the precipitation of immunogenic compositions - Google Patents

Formulations stabilizing and inhibiting the precipitation of immunogenic compositions

Info

Publication number
FR22C1027I1
FR22C1027I1 FR22C1027C FR22C1027C FR22C1027I1 FR 22C1027 I1 FR22C1027 I1 FR 22C1027I1 FR 22C1027 C FR22C1027 C FR 22C1027C FR 22C1027 C FR22C1027 C FR 22C1027C FR 22C1027 I1 FR22C1027 I1 FR 22C1027I1
Authority
FR
France
Prior art keywords
formulations
stabilizing
inhibiting
precipitation
immunogenic compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1027C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38441477&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1027(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of FR22C1027I1 publication Critical patent/FR22C1027I1/en
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55583Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018Lipids, e.g. in lipopeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6081Albumin; Keyhole limpet haemocyanin [KLH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR22C1027C 2006-04-26 2022-06-09 Formulations stabilizing and inhibiting the precipitation of immunogenic compositions Active FR22C1027I1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79526106P 2006-04-26 2006-04-26
EP07760907.1A EP2010219B1 (en) 2006-04-26 2007-04-19 Formulations which stabilize and inhibit precipitation of immunogenic compositions
PCT/US2007/066959 WO2007127665A2 (en) 2006-04-26 2007-04-19 Novel formulations which stabilize and inhibit precipitation of immunogenic compositions

Publications (1)

Publication Number Publication Date
FR22C1027I1 true FR22C1027I1 (en) 2022-09-09

Family

ID=38441477

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1027C Active FR22C1027I1 (en) 2006-04-26 2022-06-09 Formulations stabilizing and inhibiting the precipitation of immunogenic compositions

Country Status (30)

Country Link
US (3) US7935787B2 (en)
EP (5) EP3517129A1 (en)
JP (7) JP5612305B2 (en)
KR (9) KR101514913B1 (en)
CN (4) CN105879021B (en)
AR (2) AR060665A1 (en)
AU (1) AU2007243019B2 (en)
BR (2) BRPI0710918B8 (en)
CA (3) CA2873346C (en)
CL (1) CL2007001185A1 (en)
CR (1) CR10405A (en)
CY (2) CY1116966T1 (en)
DK (4) DK2679244T3 (en)
EA (2) EA017436B1 (en)
ES (4) ES2885762T3 (en)
FR (1) FR22C1027I1 (en)
HK (3) HK1196546A1 (en)
HR (3) HRP20151203T1 (en)
HU (5) HUE058394T2 (en)
IL (3) IL194753A (en)
LT (2) LT2676679T (en)
MX (3) MX359741B (en)
PL (4) PL2676679T3 (en)
PT (4) PT2679244T (en)
RU (1) RU2482878C2 (en)
SI (4) SI2679244T1 (en)
TR (1) TR201902402T4 (en)
TW (1) TW200806315A (en)
WO (1) WO2007127665A2 (en)
ZA (1) ZA200809167B (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9910089A (en) 1998-05-01 2004-06-08 Chiron Corp Compositions and antigens of neisseria meningitidis
EP2270174A1 (en) 1999-05-19 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
EP2275552B1 (en) 1999-10-29 2015-09-09 GlaxoSmithKline Biologicals SA Neisserial antigenic peptides
PT2270030E (en) 2000-02-28 2012-07-24 Novartis Vaccines & Diagnostic Heterologous expression of neisserial proteins
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
JP2011507816A (en) * 2007-12-21 2011-03-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Malaria vaccine
NZ587382A (en) 2008-02-21 2012-01-12 Novartis Ag Meningococcal fhbp polypeptides
NZ595234A (en) 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
CA2756533A1 (en) * 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
WO2010125480A1 (en) 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
PL3170508T3 (en) * 2010-06-04 2020-04-30 Wyeth Llc Vaccine formulations
US8802603B2 (en) 2010-06-17 2014-08-12 Becton, Dickinson And Company Medical components having coated surfaces exhibiting low friction and low reactivity
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
ES2850973T3 (en) 2010-08-23 2021-09-01 Wyeth Llc Stable formulations of rLP2086 antigens from Neisseria meningitidis
WO2012032489A1 (en) 2010-09-10 2012-03-15 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
FR2966044B1 (en) * 2010-10-18 2012-11-02 Sanofi Pasteur METHOD FOR CONDITIONING A VACCINE CONTAINING AN ALUMINUM ADJUVANT
TWI603739B (en) 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 Improved high concentration anti-tnfα antibody liquid formulations
CA2819366A1 (en) * 2010-12-10 2012-06-14 Merck Sharp & Dohme Corp. Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions
US10596246B2 (en) 2011-12-29 2020-03-24 Glaxosmithkline Biological Sa Adjuvanted combinations of meningococcal factor H binding proteins
SA115360586B1 (en) 2012-03-09 2017-04-12 فايزر انك Neisseria meningitidis compositions and methods thereof
NZ628449A (en) 2012-03-09 2016-04-29 Pfizer Neisseria meningitidis compositions and methods thereof
NZ630133A (en) 2012-06-14 2016-10-28 Novartis Ag Vaccines for serogroup x meningococcus
FI4002842T3 (en) 2012-06-26 2023-11-02 Lg Electronics Inc Video decoding method, video encoding method and storage medium storing encoded video information
JOP20200175A1 (en) * 2012-07-03 2017-06-16 Novartis Ag Syringe
JP6446377B2 (en) 2013-03-08 2018-12-26 ファイザー・インク Immunogenic fusion polypeptide
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SI3060256T1 (en) * 2013-10-25 2019-08-30 Bayer Pharma Aktiengesellschaft A novel stable formulation
PL3096785T3 (en) * 2014-01-21 2021-03-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112017017460A2 (en) 2015-02-19 2018-04-10 Pfizer Inc. neisseria meningitidis compositions and methods thereof
BR112017026343A2 (en) * 2015-06-08 2019-11-19 Serum Inst Of India Private Ltd methods for improving the adsorption of protein-polysaccharide conjugates and thus obtained multivalent vaccine formulation
MY192183A (en) * 2015-07-21 2022-08-05 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
KR102429287B1 (en) * 2015-12-10 2022-08-05 가부시끼가이샤 메니콘 Peptide composition
MX2019002489A (en) 2016-09-02 2019-10-21 Sanofi Pasteur Inc Neisseria meningitidis vaccine.
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
WO2018126229A2 (en) 2016-12-30 2018-07-05 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
CN106620681A (en) * 2017-01-12 2017-05-10 南京佰泰克生物技术有限公司 Cell lysis solution, kit and application of cell lysis solution to preparation of tumor whole cell antigen loaded DC tumor vaccine
CN110234658B (en) 2017-01-31 2024-03-12 辉瑞大药厂 Neisseria meningitidis compositions and methods of use thereof
US20200222550A1 (en) 2017-01-31 2020-07-16 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
CN116870144A (en) 2017-01-31 2023-10-13 默沙东有限责任公司 Method for preparing polysaccharide-protein conjugates
AU2018225083B2 (en) * 2017-02-24 2023-06-01 Merck Sharp & Dohme Llc Pneumococcal conjugate vaccine formulations
BR112019017560A2 (en) 2017-02-24 2020-04-07 Merck Sharp & Dohme enhancement of immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates
WO2018156467A1 (en) * 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Methods for improving filterability of polysaccharide-protein conjugate reactions
CN111065387B (en) 2017-09-07 2023-08-25 默沙东有限责任公司 Pneumococcal polysaccharide and its use in immunogenic polysaccharide-carrier protein conjugates
MX2020002557A (en) 2017-09-07 2020-07-13 Merck Sharp & Dohme Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates.
CN111278458A (en) * 2017-10-25 2020-06-12 默沙东公司 Adjuvant vaccines
GEP20227420B (en) 2017-12-06 2022-10-10 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
EP3787673A4 (en) 2018-04-30 2022-04-27 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
US11896656B2 (en) 2018-04-30 2024-02-13 Merck Sharp & Dohme Llc Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP2022502493A (en) * 2018-09-24 2022-01-11 バイオヴァクシーズ インコーポレイテッド (Ii) Haptenized self-vaccine and its use
JOP20210148A1 (en) 2018-12-19 2023-01-30 Merck Sharp & Dohme Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
WO2022180648A1 (en) 2021-02-26 2022-09-01 Biological E Limited Activated-quenched polysaccharide and improved methods for quantification of polysaccharide in a vaccine composition

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1189340A (en) * 1967-09-13 1970-04-22 American Cyanamid Co Antigen-Adjuvant Composition
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
SE8405493D0 (en) 1984-11-01 1984-11-01 Bror Morein IMMUNOGENT COMPLEX AND KITCHEN FOR PREPARING IT AND USING IT AS IMMUNOSTIMENTING AGENTS
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
FR2630115B1 (en) * 1988-04-14 1994-10-28 Merieux Inst PROCESS FOR STABILIZING HUMAN ALBUMIN SOLUTIONS AND SOLUTION OBTAINED
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
ATE129906T1 (en) * 1990-07-19 1995-11-15 Nardino Righi SINGLE USE SAFETY SYRINGE.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
JPH07507854A (en) 1991-12-23 1995-08-31 ツォッヒェ,ミヒャエル Engine with oil removal device
IT1253009B (en) 1991-12-31 1995-07-10 Sclavo Ricerca S R L DETOXIFIED IMMUNOGENIC MUTANTS OF COLERIC TOXIN AND TOXIN LT, THEIR PREPARATION AND USE FOR THE PREPARATION OF VACCINES
ATE188613T1 (en) 1992-06-25 2000-01-15 Smithkline Beecham Biolog VACCINE COMPOSITION CONTAINING ADJUVANTS
ES2231770T3 (en) 1993-03-05 2005-05-16 Wyeth Holdings Corporation NEW PLASMIDS FOR THE PRODUCTION OF CRM PROTEIN AND DIFTERIC TOXIN.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP3696267B2 (en) * 1994-02-28 2005-09-14 天野エンザイム株式会社 Method for stabilizing bioactive protein
DE4407489A1 (en) * 1994-03-07 1995-09-14 Bayer Ag Vaccine for the prevention of respiratory and reproductive diseases of the pig
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
UA56132C2 (en) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
US5846547A (en) * 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6355255B1 (en) * 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5932223A (en) 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
RU2098109C1 (en) * 1996-09-26 1997-12-10 Александр Григорьевич Чучалин Antiallergic, antiinflammatory agent, method of its preparing, curative and cosmetic agent and its use
JP4078406B2 (en) * 1997-01-22 2008-04-23 有限会社コーキ・エンジニアリング Method for manufacturing syringe cylinder
PT973546E (en) * 1997-04-08 2004-06-30 Merck & Co Inc STABILIZED FORMULATIONS OF HUMAN PAPILOMA VIRUS
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
FR2763244B1 (en) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc MULTIVALENT VACCINE COMPOSITION WITH MIXED CARRIER
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
CA2264970A1 (en) * 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
DK1117435T3 (en) 1998-09-30 2008-03-17 Wyeth Corp Mutated cholera-holotoxin as adjuvant
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
CZ303653B6 (en) 1999-03-19 2013-01-30 Smithkline Beecham Biologicals S. A. Immunogenic composition
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
DK1233784T3 (en) * 1999-12-02 2008-09-01 Novartis Vaccines & Diagnostic Preparations and Methods for Stabilizing Biological Molecules after Lyophilization
DE10012370A1 (en) * 2000-03-14 2001-09-27 Chiron Behring Gmbh & Co Use of oil-in-water emulsion as vaccine adjuvant, particularly for influenza and pneumococcal vaccines, administered at different site from the vaccine
SK287689B6 (en) 2000-06-08 2011-06-06 Intercell Ag Immunostimulatory oligodeoxynucleotides
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
PT1296715E (en) * 2000-06-29 2012-01-19 Smithkline Beecham Biolog Multivalent vaccine composition
KR100385711B1 (en) * 2000-07-05 2003-05-27 녹십자백신 주식회사 The quadrivalent combination vaccine including diphtheria toxoid, tetanus toxoid, whole cell pertussis and hepatitis b surface antigen and the preparation thereof
JP4703091B2 (en) * 2000-07-10 2011-06-15 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ,センターズ フォー Multiple antigenic peptides that are immunogenic against Streptococcus pneumoniae
GB0025414D0 (en) * 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
AT410635B (en) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh VACCINE COMPOSITION
WO2002074325A1 (en) * 2001-03-19 2002-09-26 Iomai Corporation Patch for transcutaneous immunization
IL159209A0 (en) 2001-06-07 2004-06-01 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
CN1977971A (en) 2001-06-07 2007-06-13 惠氏控股有限公司 Mutant forms of cholera holotoxin as an adjuvant
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
RU2323002C2 (en) * 2001-07-26 2008-04-27 Чирон Срл. Vaccines comprising aluminum adjuvants and histidine
MX339524B (en) * 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
PT1441589E (en) * 2001-11-08 2012-08-13 Abbott Biotherapeutics Corp Stable liquid pharmaceutical formulation of igg antibodies
WO2004065603A2 (en) 2003-01-15 2004-08-05 Wyeth Holdings Corporation Methods for increasing neisseria protein expression
WO2004067030A2 (en) * 2003-01-30 2004-08-12 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
MY162623A (en) * 2003-02-10 2017-06-30 Biogen Ma Inc Immunoglobulin formulation and method of preparation thereof
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
EP1618185A4 (en) * 2003-04-16 2009-05-27 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease
PE20050232A1 (en) * 2003-06-25 2005-04-01 Elan Pharm Inc METHOD AND COMPOSITIONS TO TREAT RHEUMATOID ARTHRITIS
UA67144A (en) 2003-07-29 2004-06-15 Inst Exprm & Clinical Veterina Method for production of inactivated vaccine against salmonellosis and escherichiosis of animals
CN100423774C (en) 2003-08-06 2008-10-08 美国政府健康及人类服务部 Process for preparing polysaccharide-protein conjugate vaccines
DE10348550A1 (en) * 2003-10-20 2005-06-16 Hexal Biotech Forschungsgmbh Stable aqueous G-CSF-containing compositions
RU37462U1 (en) 2004-01-16 2004-04-27 Бычкова Ольга Владимировна TEST
AU2005302269B2 (en) * 2004-11-01 2011-05-19 The Brigham And Women's Hospital, Inc. Modified streptococcal polysaccharides and uses thereof
CA2595380A1 (en) * 2005-01-28 2006-08-03 Wyeth Stabilized liquid polypeptide formulations
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN102716480B (en) * 2005-04-08 2023-03-21 惠氏有限责任公司 Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
WO2007127668A2 (en) 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP2589392B1 (en) 2008-03-05 2016-11-30 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition

Also Published As

Publication number Publication date
EP2676679A3 (en) 2014-01-01
DK2679245T3 (en) 2021-09-06
HK1196546A1 (en) 2014-12-19
BR122020000285B1 (en) 2023-05-09
HUE058394T2 (en) 2022-08-28
EP2679245A3 (en) 2014-01-15
JP2018123145A (en) 2018-08-09
ES2712956T3 (en) 2019-05-16
JP6321094B2 (en) 2018-05-09
PL2679245T3 (en) 2021-11-08
US20130034580A1 (en) 2013-02-07
AR110731A2 (en) 2019-04-24
EP2679245A2 (en) 2014-01-01
AU2007243019A1 (en) 2007-11-08
HRP20190198T1 (en) 2019-04-05
EP2010219A2 (en) 2009-01-07
KR20200032268A (en) 2020-03-25
WO2007127665A3 (en) 2008-11-13
KR20140004258A (en) 2014-01-10
JP2014221806A (en) 2014-11-27
EP2679245B1 (en) 2021-07-28
LTPA2022509I1 (en) 2022-06-27
EP2010219B1 (en) 2015-10-28
JP6192115B2 (en) 2017-09-06
CN103768615B (en) 2016-06-01
HRP20151203T1 (en) 2015-12-04
CN105879021B (en) 2020-11-24
WO2007127665A2 (en) 2007-11-08
KR20090017537A (en) 2009-02-18
SI2010219T1 (en) 2015-12-31
JP2019194240A (en) 2019-11-07
CA2873346A1 (en) 2007-11-08
MX2008013572A (en) 2009-03-06
JP2014055169A (en) 2014-03-27
SI2679244T1 (en) 2022-05-31
IL239978B (en) 2019-06-30
JP2009535353A (en) 2009-10-01
EP2676679A2 (en) 2013-12-25
MX2018012171A (en) 2021-12-08
LT2676679T (en) 2019-03-12
DK2676679T3 (en) 2019-03-04
TW200806315A (en) 2008-02-01
HUS2200028I1 (en) 2022-07-28
PT2679244T (en) 2022-04-19
PL2010219T3 (en) 2016-03-31
CA2873346C (en) 2017-09-05
EA201200929A1 (en) 2013-05-30
AR060665A1 (en) 2008-07-02
PL2679244T3 (en) 2022-06-20
KR101514913B1 (en) 2015-04-23
EP3517129A1 (en) 2019-07-31
KR20140132779A (en) 2014-11-18
CN103768615A (en) 2014-05-07
ZA200809167B (en) 2009-06-24
SI2676679T1 (en) 2019-03-29
CR10405A (en) 2009-02-26
PL2676679T3 (en) 2019-06-28
CN105879021A (en) 2016-08-24
DK2010219T3 (en) 2016-01-11
HUE055682T2 (en) 2021-12-28
CN101500612B (en) 2013-12-25
US20070253984A1 (en) 2007-11-01
EP2676679B1 (en) 2019-01-02
IL239788A0 (en) 2015-08-31
TR201902402T4 (en) 2019-03-21
PT2010219E (en) 2016-01-29
KR101514913B9 (en) 2022-07-20
KR20160049063A (en) 2016-05-04
JP2021176910A (en) 2021-11-11
SI2679245T1 (en) 2021-11-30
JP5612305B2 (en) 2014-10-22
MX359741B (en) 2018-10-09
KR20180130004A (en) 2018-12-05
EP2679244A2 (en) 2014-01-01
US8562999B2 (en) 2013-10-22
EA200870480A1 (en) 2009-04-28
US20110172393A1 (en) 2011-07-14
BRPI0710918B8 (en) 2021-05-25
CY1116966T1 (en) 2017-04-05
EA017436B1 (en) 2012-12-28
HUE042923T2 (en) 2019-07-29
CN104857524B (en) 2018-08-28
PT2679245T (en) 2021-09-02
CA2803111C (en) 2015-06-16
HRP20211417T1 (en) 2021-12-10
KR20220061256A (en) 2022-05-12
HK1223569A1 (en) 2017-08-04
PT2676679T (en) 2019-03-01
KR20210111326A (en) 2021-09-10
AU2007243019B2 (en) 2012-06-21
ES2910432T3 (en) 2022-05-12
HK1209358A1 (en) 2016-04-01
CN104857524A (en) 2015-08-26
EP2679244A3 (en) 2014-01-15
JP2016222701A (en) 2016-12-28
CN101500612A (en) 2009-08-05
RU2482878C2 (en) 2013-05-27
KR101514847B1 (en) 2015-04-24
BRPI0710918B1 (en) 2021-02-02
CA2803111A1 (en) 2007-11-08
IL194753A (en) 2015-08-31
CL2007001185A1 (en) 2008-01-18
ES2885762T3 (en) 2021-12-15
ES2557504T3 (en) 2016-01-26
RU2008141680A (en) 2010-06-10
KR102093269B1 (en) 2020-04-23
HUE028137T2 (en) 2016-11-28
EP2679244B1 (en) 2022-03-23
CA2650056C (en) 2013-07-16
CY1121251T1 (en) 2020-05-29
IL239978A0 (en) 2015-08-31
KR20170122857A (en) 2017-11-06
DK2679244T3 (en) 2022-04-11
BRPI0710918A2 (en) 2012-03-06
US7935787B2 (en) 2011-05-03
IL194753A0 (en) 2009-08-03
EA023470B1 (en) 2016-06-30
CA2650056A1 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
FR22C1027I1 (en) Formulations stabilizing and inhibiting the precipitation of immunogenic compositions
BRPI0913379A2 (en) solid pharmaceutical formulations comprising bibw 2992
IL190885A0 (en) Immunogenic compositions and methods of use
IL195237A0 (en) Conjugates of aziridinyl-epothilone analogs and pharmaceutical compositions comprising same
BRPI1014854A2 (en) "polymer-agent conjugates, particles, compositions, and related methods of use"
HK1134679A1 (en) Compositions and methods for the treatment of infections
IL193074A0 (en) Stable pharmaceutical formulations of montelukast sodium
NO343748B1 (en) Cyclopamine analogues and pharmaceutical compositions comprising such
IL198513A0 (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
HK1134774A1 (en) Formulations of peg-interferon alpha conjugates peg-
ATE502682T1 (en) FIRE-FIGHTING COMPOSITION AND FORMULATIONS FROM THIS COMPOSITION
EP2076281A4 (en) Stabilizing alkylglycoside compositions and methods thereof